Recovery and acquisitions drive growth at Medica

‘Robust recovery’ in its core teleradiology business and strong performance from acquisitions fuelled a 68% leap in revenue at listed teleradiology business Medica Group in FY 2021. The results, which include nine months trading from its acquisition of US-based clinical trials business RadMD, reflect demand recovery following subdued trading in 2020 due to the Covid-19 pandemic….

You must be a HM Subscriber to view this content.

Subscribe Now »